BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martín-Antonio B, Suñe G, Najjar A, Perez-Amill L, Antoñana-Vildosola A, Castella M, León S, Velasco-de Andrés M, Lozano F, Lozano E, Bueno C, Estanyol JM, Muñoz-Pinedo C, Robinson SN, Urbano-Ispizua A. Extracellular NK histones promote immune cell anti-tumor activity by inducing cell clusters through binding to CD138 receptor. J Immunother Cancer 2019;7:259. [PMID: 31619273 DOI: 10.1186/s40425-019-0739-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Hervás-salcedo R, Martín-antonio B. A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments. Cancers 2022;14:3796. [DOI: 10.3390/cancers14153796] [Reference Citation Analysis]
2 Serrano-López J, Martín-Antonio B. Inflammaging, an Imbalanced Immune Response That Needs to Be Restored for Cancer Prevention and Treatment in the Elderly. Cells 2021;10:2562. [PMID: 34685542 DOI: 10.3390/cells10102562] [Reference Citation Analysis]
3 Etxebeste-Mitxeltorena M, Del Rincón-Loza I, Martín-Antonio B. Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner. Front Immunol 2021;12:717850. [PMID: 34447383 DOI: 10.3389/fimmu.2021.717850] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
4 Bachiller M, Perez-Amill L, Battram AM, Carné SC, Najjar A, Verhoeyen E, Juan M, Urbano-Ispizua A, Martin-Antonio B. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness. J Immunother Cancer 2021;9:e002866. [PMID: 34433634 DOI: 10.1136/jitc-2021-002866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jia H, Zhang X, Liu X, Qiao R, Liu Y, Lv S, Zhu H, Wang J, Kong Q, Zhang H, Zhang Z. FABP5, a Novel Immune-Related mRNA Prognostic Marker and a Target of Immunotherapy for Multiple Myeloma. Front Med (Lausanne) 2021;8:667525. [PMID: 34249967 DOI: 10.3389/fmed.2021.667525] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Bachiller M, Battram AM, Perez-Amill L, Martín-Antonio B. Natural Killer Cells in Immunotherapy: Are We Nearly There? Cancers (Basel) 2020;12:E3139. [PMID: 33120910 DOI: 10.3390/cancers12113139] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
7 Battram AM, Bachiller M, Martín-Antonio B. Senescence in the Development and Response to Cancer with Immunotherapy: A Double-Edged Sword. Int J Mol Sci 2020;21:E4346. [PMID: 32570952 DOI: 10.3390/ijms21124346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
8 Wu Y, Li J, Jabbarzadeh Kaboli P, Shen J, Wu X, Zhao Y, Ji H, Du F, Zhou Y, Wang Y, Zhang H, Yin J, Wen Q, Cho CH, Li M, Xiao Z. Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy. Pharmacological Research 2020;155:104691. [DOI: 10.1016/j.phrs.2020.104691] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]